Minapharm Pharmaceuticals S.A.E. specializes in developing, manufacturing and marketing prescription pharmaceutical products. The products are for the treatment of gastroenterological, ophthalmologic, cardiovascular, genetic, dermatological, orthopedic diseases, etc.

Employees

Sector

Pharmaceuticals

Calendar

08-12 Ex-dividend date - 1.25 EGP

More about the company

Quotes

Date	Price	Change	Volume
26-08-01	EGP 781.20	+5.55%	8,069
26-07-30	EGP 740.09	+0.64%	1,390
26-07-29	EGP 735.41	-1.03%	2,123
26-07-28	EGP 743.05	-1.37%	741
26-07-27	EGP 753.40	+2.45%	1,891

End-of-day quote Egyptian Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Egyptian Exchange Other stock markets 2026-08-02			5-day change	1st Jan Change
781.20 ^EGP	+5.55%		+4.62%	+123.71%

06-10	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE

Market Cap	9.2B 180M 156M 146M 134M 252M 17.18B 256M 1.72B 674M 8.55B 676M 661M 28.67B	P/E 2024	14x	P/E 2025	584x
Enterprise Value	10.31B 202M 175M 163M 150M 283M 19.25B 287M 1.92B 755M 9.58B 757M 741M 32.13B	EV / Sales 2024	0.78x	EV / Sales 2025	0.81x
Free-Float	14.5%	Yield 2024	1.54%	Yield 2025	-

06-10	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE
11-30	Minapharm Pharmaceuticals Q3 consol profit egp 16.8 million	RE
11-29	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-14	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-09-14	Minapharm Pharmaceuticals Q2 consol profit EGP 40 million	RE
25-07-27	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-07-27	Minapharm Pharmaceuticals Q1 consol net loss EGP 2 million	RE
25-06-12	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-06-12	Minapharm Pharmaceuticals FY Colsol Net Profit EGP 161.1 Million	RE
25-05-26	Minapharm Pharmaceuticals FY Standalone Profit EGP 162.8 Million	RE
24-12-03	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-09-01	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

25-07-07	EBRD, Admaius Capital plan to acquire 15%-20% of Egyptian Minapharm Pharmaceuticals	AQ
25-03-26	African Development Bank Approves Eur 15 Million Loan to Boost Biosimilars' Development and Production in Egypt	AQ
23-10-05	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries	AQ
23-10-04	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia	AQ
23-03-06	Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa	AQ

MINAPHARM Pharmaceuticals Stock

Stocks

MIPH

EGS380G1C011

Pharmaceuticals

Valuation: MINAPHARM Pharmaceuticals

Chart: MINAPHARM Pharmaceuticals

Latest news : MINAPHARM Pharmaceuticals

Press Releases: MINAPHARM Pharmaceuticals

Quotes and Performance

Course Extremes

Managers and Directors: MINAPHARM Pharmaceuticals

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+5.55%
1 week	+4.62%
Current month	+5.55%
1 month	+18.64%
3 months	+16.95%
6 months	+135.93%
Current year	+123.71%

1 week	725	784.99
1 month	650	784.99
Current year	320.23	784.99
1 year	230	784.99
3 years	145	784.99
5 years	97	784.99
10 years	45	784.99

Manager	Title	Age	Since
Shaheer Wafeeq Sa'ad Al-Bardissy CEO	Chief Executive Officer	-	-
Wafik El-Bardissy CEO	Chief Executive Officer	-	2010-10-18
Rafiq Raymond DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Wafik El-Bardissy CHM	Chairman	-	2010-10-17
Anwar Nasr Mekhaeel BRD	Director/Board Member	-	2010-10-17
Amr Mohamed Sobhi Hamza El-Shabrawishy BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MINAPHARM PHARMACEUTICALS	+5.55%	+4.62%	+228.24%	+262.79%	170M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.53%	+2.54%	+22.14%	+74.08%	50.03B
OTSUKA HOLDINGS CO., LTD.	-1.81%	-0.49%	+48.83%	+107.71%	36.6B
CIPLA LIMITED	+0.46%	+4.44%	-1.97%	+25.02%	12.47B
ZYDUS LIFESCIENCES LIMITED	+1.05%	+1.63%	+18.73%	+77.76%	11.77B
KRKA, D. D.	-1.33%	-0.76%	+30.73%	+127.63%	9.04B
ONO PHARMACEUTICAL CO., LTD.	-2.99%	-2.09%	+45.28%	-11.87%	7.03B
GEDEON RICHTER	+0.51%	+1.46%	+13.46%	+32.06%	6.79B
GLENMARK PHARMACEUTICALS LIMITED	+1.99%	+1.91%	+8.03%	+183.42%	6.6B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+0.39%	+3.39%	-35.25%	+4.49%	5.49B
Average	+0.33%	+1.24%	+37.82%	+88.31%	14.6B
Weighted average by Cap.	-0.60%	+1.28%	+25.18%	+78.39%

	2024	2025
Net sales	5.66B 111M 96.28M 89.61M 82.27M 155M 10.57B 158M 1.06B 415M 5.26B 416M 407M 17.65B	6.44B 126M 109M 102M 93.51M 177M 12.02B 179M 1.2B 471M 5.98B 473M 462M 20.06B
Net income	157M 3.07M 2.67M 2.48M 2.28M 4.31M 293M 4.37M 29.29M 11.49M 146M 11.53M 11.28M 489M	40.22M 786K 683K 636K 584K 1.1M 75.06M 1.12M 7.5M 2.94M 37.37M 2.95M 2.89M 125M
Net Debt	2.6B 50.8M 44.16M 41.1M 37.74M 71.26M 4.85B 72.36M 484M 190M 2.41B 191M 187M 8.09B	1.11B 21.7M 18.87M 17.56M 16.12M 30.45M 2.07B 30.92M 207M 81.24M 1.03B 81.51M 79.72M 3.46B